Imagion Biosystems has lodged Appendix 3B: New issue announcement, application for quotation of additional securities and agreement.
View Appendix 3B.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance